NEW YORK – Diagnostics firm Enzyre said on Tuesday it has received a €1.4 million ($1.6 million) loan from the Dutch government.
The Corona Bridge Loan was granted in support of innovative startups and scaleups, said Enzyre, a spinout of Radboud University Medical Center in the Netherlands. Novalis Biotechnology Incubation participated in the financing as a co-financer through its seed fund.
Enzyre is developing a near-patient platform called Enzypad to measure up to 12 biomarkers in body fluids with the first application expected to be the monitoring of hemophilia. The system, the firm said, will provide a real-time picture of a patient's blood coagulation status, and test results will be sent automatically to the treating physician through a mobile phone app.
The system consists of a blood sampling device, single-use microfluidic cartridge with reagents and controls, and a small reusable processor that enables reagent flow, processes test results, and transfers results immediately to the cloud, according to Enzyre's website.
In December 2019, Enzyre and Takeda entered into a collaboration to develop Enzypad for congenital bleeding disorders.